

To the shareholders of Nordic Nanovector ASA

NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF NORDIC NANOVECTOR ASA

Notice is hereby served that an extraordinary general meeting of Nordic Nanovector ASA, (the "**Company**") will be held on 1 December 2022 at 10:00 hours (CET) at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo.

The general meeting will be opened by the chairman of the board of directors, Jan Hendrik Egberts, or a person appointed by the board of directors cf. Section 5-12 of the Norwegian Public Limited Liability Companies Act.

The following matters are on the agenda:

- | | |
|--|---|
| 1. Election of a chairperson for the meeting and a person to co-sign the minutes | 4. Approval of share capital increase |
| 2. Approval of the notice and the agenda | 5. Change of objective |
| 3. Approval of transaction agreement | 6. Election of new Board of Directors |
| | 7. Authorisation to the Board to increase the share capital by up to 20% for other specified purposes |

Nordic Nanovector ASA is a public limited company subject to the rules of the Norwegian Public Limited Companies Act. As of the date of this notice, the Company has issued 116,035,298 shares, each of which represents one vote. The shares have equal rights also in all other respects.

Pursuant to Section 7 of the Company's Articles of Association, the Board has decided that shareholders wishing to attend the General Meeting (in person or by proxy) must give notice to the Company of this by sending the enclosed registration form (which is also available on the Company's website as set out below) to the Company, c/o the Company's security account manager, Nordea Bank Abp, Norwegian branch, Issuer Services, by letter to the following address: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail to: nis@nordea.com. The notice of attendance must have been received no later than 29 November 2022 at 16:00 hours (CET). Any failure to register within the deadline may result in the shareholder being denied access to the general meeting.

Shareholders may participate at the general meeting electronically. The Company still encourages shareholders to vote in advance or submit proxies with voting instructions in advance of the general meeting, as further described below. Shareholders who wish to participate electronically must notify the Company of this by e-mail to legal@nordicnanovector.com no later than 29 November 2022 at 16:00 hours (CET). Practical information for such participation will be provided to those it concerns before the general meeting.

Shareholders that are prevented from attending may be represented by proxy. The proxy form, including detailed instructions for the use of the form, is enclosed to this notice and

is available on the Company's website as set out below. If desirable, proxy may be given to the Chairman of the Board, Jan Hendrik Egberts. Completed proxy forms may either be submitted at the general meeting or sent to the Company's security account manager, Nordea Bank Abp, Norwegian branch, Issuer Services within 29 November 2022 at 16:00 hours (CET) by letter to the following address: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail: nis@nordea.com.

A shareholder who cannot attend the general meeting may in advance cast a vote on each agenda item via www.nordicnanovector.com and Euronext Securities Oslo (formerly VPS) ("ESO") Investor Services. The deadline for prior voting is 29 November 2022 at 16:00 hours (CET). Until the deadline, votes already cast may be changed or withdrawn. Votes already cast prior to the general meeting will be considered withdrawn if the shareholder attends the general meeting in person or by proxy.

If shares are registered on a nominee account in the ESO register, cf. Section 4-10 of the Norwegian Public Limited Companies Act, and the beneficial shareholder wants to vote for its shares, the beneficial shareholder must re-register the shares in a separate ESO account in its own name prior to the General Meeting, or prove that the transfer to such account has been reported to the ESO prior to the General Meeting.

A shareholder may make proposals for resolutions with respect to matters on the agenda and may require that members of the Board and the CEO at the general meeting provide available information about matters which may affect the assessment of (i) the approval of the annual accounts and the Board's annual report, (ii) matters that are presented to the shareholders for decision and (iii) the Company's financial situation, including operations in other companies the Company participates in, and other matters to be discussed at the general meeting, unless the requested information cannot be disclosed without causing disproportionate damage to the Company.

This notice, other documents regarding matters to be discussed in the general meeting, including the documents to which this notice refers, as well as the Company's Articles of Association, are available on the Company's website www.nordicnanovector.com. Shareholders may contact the Company by mail, e-mail or telephone in order to request the documents in question on paper. Address: Nordic Nanovector ASA, Kjelsåsveien 168B, N-0884 Oslo, Norway, e-mail: ir@nordicnanovector.com, telephone: +47 22 18 33 01.

The following documents are available at www.nordicnanovector.com:

- This notice and the enclosed form for notice of attendance/proxy
- The Board of Directors' proposed resolutions for the items listed on the agenda
- A company presentation for the transaction agreement to be dealt with by the general meeting
- An expert statement pursuant to the Norwegian Public Limited Liability Companies Act section 10-2 (3), cf. section 2-6 in relation to the proposed share capital increase

Oslo, 10 November 2022
On behalf of the Board of Directors of Nordic Nanovector ASA

Jan Hendrik Egberts
Chairman

Appendices:

- Form of registration
- Form of proxy

**NORDIC NANOVECTOR ASA
NOTICE OF ATTENDANCE
EXTRAORDINARY GENERAL MEETING 1 DECEMBER 2022**

Shareholders who wish to attend the Extraordinary General Meeting to be held on 29 November 2022 are requested to fill in and return this notice of attendance to: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway or E-mail: nis@nordea.com.

Attendance may also be registered electronically through ESO Investor Services.

Notification of attendance must be received by Nordea no later than 29 November 2022 at 16:00 hours (CET).

The undersigned wishes to attend the Extraordinary General Meeting on 1 December 2022 at 10:00 hours (CET).

Name of shareholder _____

Representative for a shareholder
(if a corporation) _____

_____ Date	_____ Place	_____ Shareholder's signature
---------------	----------------	----------------------------------

If the shareholder is a company, please attach documentation in the form of certificate of registration, or separate power of attorney.

**NORDIC NANOVECTOR ASA
POWER OF ATTORNEY
EXTRAORDINARY GENERAL MEETING 1 DECEMBER 2022**

Shareholders who do not return the form "NOTICE OF ATTENDANCE – EXTRAORDINARY GENERAL MEETING 1 DECEMBER 2022" (see the previous page), and therefore wishes to authorise another person to act on his or her behalf at the Extraordinary General Meeting on 1 December 2022 must complete this power of attorney form and return it to: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or E-mail: nis@nordea.com.

Powers of attorney may also be registered electronically through ESO Investor Services.

The power of attorney must be received by Nordea no later than 29 November 2022 at 16:00 hours (CET).

The undersigned hereby grants (please tick):

☐

The Chairman of the Board, Jan Hendrik Egberts, or the person he appoints, or

☐

Name of attorney (*please use capital letters*)

power of attorney to attend and vote for my/our shares at the Extraordinary General Meeting of Nordic Nanovector ASA to be held on 1 December 2022 at 10:00 hours (CET). If the power of attorney form is submitted without stating the name of the attorney, the power of attorney will be deemed to have been given to the Chairman of the Board Jan Hendrik Egberts or the person he appoints. Neither the Company nor the Chairman of the Board (and whoever the Chairman of the Board appoints) can be held responsible for any loss resulting from the proxy form not being received by the proxy in time. The Company and the Chairman of the board (and whoever the Chairman of the board appoints) are not responsible for ensuring that votes will be cast in accordance with the proxy form and have no responsibility in connection with cast of votes pursuant to the proxy form.

The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the attorney determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice. If the voting instruction is unclear, the holder will exercise his power of attorney based on a for the holder reasonable assessment of the instruction. If such assessment is not possible, the holder may abstain from voting.

Item:	In favour	Against	Abstain	At the attorney's discretion
1. Election of the chairman for the meeting				
1. Election of one person to co-sign the minutes				
2. Approval of the notice and the agenda of the meeting				
3. Approval of transaction agreement				
4. Approval of share capital increase				
5. Change of objective				
6. Election of Jan H. Egberts as member and chairman of the board				
6. Election of Malene Brondberg as a board member				
6. Election of Erlend Skagseth as a board member				
6. Election of Gökhan Batur as a board member				
6. Election of a board member to be proposed				
7. Authorisation to the Board to increase the share capital by 20% for other specified purposes				

Name of shareholder _____

Representative for a shareholder
(if a corporation) _____

Date Place Shareholder's signature

If the shareholder is a company, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.

**PROTOKOLL FRA EKSTRAORDINÆR
GENERALFORSAMLING****I****NORDIC NANOVECTOR ASA****ORG. NR. 994 297 422**

Det ble avholdt ekstraordinær generalforsamling i Nordic Nanovector ASA ("**Selskapet**") den 1. desember 2022, kl. 10.00 hos Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo.

Generalforsamlingen ble åpnet av advokat Bjørn Gabriel Reed, som opptok en fortegnelse over de møtende aksjonærer.

47 278 974 av totalt 116 035 298 aksjer og stemmer i Selskapet var representert, tilsvarende 40,75 % av samtlige aksjer. En oversikt over de møtende aksjonærene er inntatt som Vedlegg 1 til protokollen.

Stemmegivning for de enkelte saker på dagsordenen er vedlagt protokollen som Vedlegg 2.

Generalforsamlingen gikk så over til å behandle følgende dagsorden:

Dagsorden:**1. Valg av møteleder og en person til å medundertegne protokollen**

Bjørn Gabriel Reed ble valgt som møteleder og Fredrik Haavind ble valgt til å medundertegne protokollen.

2. Godkjennelse av innkallingen og dagsorden

Det ble opplyst at innkallingen var blitt tilsendt samtlige aksjonærer med kjent oppholdssted den 10. november 2022.

Innkallingen og dagsorden ble godkjent.

Møtelederen erklærte generalforsamlingen for lovlig satt.

(OFFICE TRANSLATION)

**MINUTES OF EXTRAORDINARY
GENERAL MEETING****OF****NORDIC NANOVECTOR ASA****REG. NO. 994 297 422**

The annual general meeting of Nordic Nanovector ASA, (the "**Company**") was held on 1 December 2022, at 10:00 hours CET at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo..

The general meeting was opened by lawyer Bjørn Gabriel Reed, who registered the attending shareholders.

47,278,974 of a total of 116,035,298 shares were represented at the general meeting, equal to 40.75% of the total number of shares. An overview over the attending shareholders is attached to the minutes as Appendix 1.

The voting for each of the items on the agenda is attached to the minutes as Appendix 2.

The meeting discussed the following matters:

Agenda:**1. Election of a chairperson for the meeting and a person to co-sign the minutes**

Bjørn Gabriel Reed was elected as chairperson and Fredrik Haavind was elected to co-sign the minutes.

2. Approval of the notice and the agenda

It was informed that the notice of the general meeting had been sent to all shareholders with a known address on 10 November 2022.

The notice and the agenda were approved.

The chairperson declared the general meeting as lawfully convened.

3. Godkjenning av transaksjonsavtale

Styrets forslag til vedtak oppnådde ikke tilstrekkelig flertall av stemmer og ble dermed nedstemt av generalforsamlingen.

Etter forslag fra møteleder og samtykke fra generalforsamlingen ble det ikke stemt over sak 4, 5, 6 og 7 på agendaen etter at det foreslåtte vedtaket under sak 3 ble nedstemt.

4. Godkjenning av kapitalforhøyelse

Med henvisning til sak 3 ble det ikke avholdt avstemning.

5. Endring av formålsbestemmelse

Med henvisning til sak 3 ble det ikke avholdt avstemning.

6. Valg av nytt styre

Med henvisning til sak 3 ble det ikke avholdt avstemning.

7. Fullmakt til styret til å forhøye aksjekapitalen med opp til 20% for andre angitte formål

Med henvisning til sak 3 ble det ikke avholdt avstemning.

Det var ikke flere saker på dagsorden. Generalforsamlingen ble deretter hevet og protokollen undertegnet.

3. Approval of transaction agreement

The Board of Directors proposed resolution did not obtain a sufficient majority of votes and was thus voted down by the general meeting.

Following a proposal from the chairman of the meeting and consent from the General Meeting, items 4, 5, 6 and 7 on the agenda were not subject to vote after the proposed resolution in item 3 was voted down.

4. Approval of share capital increase

With reference to item 3 it was not conducted a vote.

5. Change of the Company's objective

With reference to item 3 it was not conducted a vote.

6. Election of new Board of Directors

With reference to item 3 it was not conducted a vote.

7. Authorisation to the Board to increase the share capital by up to 20% for other specified purposes

With reference to item 3 it was not conducted a vote.

There were no further matters to be resolved. The meeting was adjourned and the minutes were signed.

In case of any discrepancies between the Norwegian text and the English translation, the Norwegian text shall prevail.

Oslo,

1. desember / 1 December 2022

Vedlegg:

1	Oversikt over antall aksjer og stemmer representert	1
2	Avstemmingsresultater	2
3	Tegningsliste	3
4	Sakkyndig redegjørelse i henhold til allmennaksjeloven § 10-2 (3), jf. § 2-6	4

Appendices:

1	Overview of the number of shares and votes represented	1
2	Voting results	2
3	List of subscribers	3
4	Expert statement pursuant to the Norwegian Public Limited Liability Companies Act section 10-2 (3), cf. section 2-6	4

Total Represented

ISIN: NO0010597883 NORDIC NANOVECTOR ASA
General meeting date: 01/12/2022 10.00
Today: 01.12.2022

Number of persons with voting rights represented/attended : 19

	Number of shares	% sc
Total shares	116,035,298	
- own shares of the company	0	
Total shares with voting rights	116,035,298	
Represented by own shares	24,214,946	20.87 %
Represented by advance vote	15,048,338	12.97 %
Sum own shares	39,263,284	33.84 %
Represented by proxy	5,956,565	5.13 %
Represented by voting instruction	2,059,125	1.78 %
Sum proxy shares	8,015,690	6.91 %
Total represented with voting rights	47,278,974	40.75 %
Total represented by share capital	47,278,974	40.75 %

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

NORDIC NANOVECTOR ASA

Protocol for general meeting NORDIC NANOVECTOR ASA

ISIN: NO0010597883 NORDIC NANOVECTOR ASA
 General meeting date: 01/12/2022 10.00
 Today: 01.12.2022

Shares class	FOR	Against	Abstain	Poll in	Poll not registered	Represented shares with voting rights
Agenda item 1 Election of the chairman for the meeting						
Ordinær	45,922,952	218,997	1,137,025	47,278,974	0	47,278,974
votes cast in %	97.13 %	0.46 %	2.41 %			
representation of sc in %	97.13 %	0.46 %	2.41 %	100.00 %	0.00 %	
total sc in %	39.58 %	0.19 %	0.98 %	40.75 %	0.00 %	
Total	45,922,952	218,997	1,137,025	47,278,974	0	47,278,974
Agenda item 1.1 Election of one person to co-sign the minutes						
Ordinær	46,136,811	289,017	853,146	47,278,974	0	47,278,974
votes cast in %	97.58 %	0.61 %	1.80 %			
representation of sc in %	97.58 %	0.61 %	1.80 %	100.00 %	0.00 %	
total sc in %	39.76 %	0.25 %	0.74 %	40.75 %	0.00 %	
Total	46,136,811	289,017	853,146	47,278,974	0	47,278,974
Agenda item 2 Approval of the notice and the agenda of the meeting						
Ordinær	45,733,545	650,047	895,382	47,278,974	0	47,278,974
votes cast in %	96.73 %	1.38 %	1.89 %			
representation of sc in %	96.73 %	1.38 %	1.89 %	100.00 %	0.00 %	
total sc in %	39.41 %	0.56 %	0.77 %	40.75 %	0.00 %	
Total	45,733,545	650,047	895,382	47,278,974	0	47,278,974
Agenda item 3 Approval of transaction agreement						
Ordinær	18,693,166	28,491,269	92,539	47,276,974	2,000	47,278,974
votes cast in %	39.54 %	60.27 %	0.20 %			
representation of sc in %	39.54 %	60.26 %	0.20 %	100.00 %	0.00 %	
total sc in %	16.11 %	24.55 %	0.08 %	40.74 %	0.00 %	
Total	18,693,166	28,491,269	92,539	47,276,974	2,000	47,278,974

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

NORDIC NANOVECTOR ASA

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	116,035,298	0.20	23,207,059.60	Yes
Sum:				

§ 5-17 Generally majority requirement
 requires majority of the given votes

§ 5-18 Amendment to resolution
 Requires two-thirds majority of the given votes
 like the issued share capital represented/attended on the general meeting

**NORDIC NANOVECTOR ASA
PROPOSED RESOLUTIONS FOR THE EXTRAORDINARY GENERAL MEETING OF
NORDIC NANOVECTOR ASA ON 1 DECEMBER 2022**

Item 1 Election of a chairperson for the meeting and a person to co-sign the minutes

The Board of Directors proposes that a person present at the General Meeting is elected as chairperson of the meeting, and that a person present is elected to co-sign the minutes.

Item 2 Approval of the notice and the agenda

Item 3 Approval of transaction agreement

Reference is made to the stock exchange announcement on 9 November 2022 regarding the Company entering into an agreement (the "**Agreement**") for the purchase of 100% of the shares in APIM Therapeutics AS (the "**Transaction**"). The purchase is to be settled by set-off of a loan note issued by the Company against issuance of new shares in the Company. Further reference is made to the presentation of the Transaction made available on the Company's website whereby the further terms of the Transaction and the combined group are presented.

As part of the implementation of the Transaction, resolutions as specified in items 4 to 6 on the agenda are required to be resolved.

The Agreement entails inter alia that the current shareholders of the Company will be diluted to hold approximately 24% of the Company's shares after the combination.

Considering that the Agreement will imply an expansion of the Company's business activities, and the Board of Directors has proposed an adjustment of the Company's object as set out in the Articles of Association, the Board of Directors presents the Agreement and the Transaction for the General Meeting's approval.

The Board proposes that the General Meeting passes the following resolution:

The agreement for the purchase of shares in APIM Therapeutics AS is approved.

Item 4 Approval of share capital increase

Reference is made to the statement under item 3.

The expert statement pursuant to the Norwegian Public Limited Liability Companies Act section 10-2 (3), cf. section 2-6 regarding the issuance of shares by set off in the Transaction is made available on the Company's website.

Following end of the financial year 2021, the Company has announced the discontinuation of its Phase 2b clinical trial of Betalutin, and related reorganizations. Further information regarding these matters have been publicly disclosed and reference is made to the presentation of the Transaction and stock exchange announcements published on the Company's ticker on www.newsweb.no.

Other than the above and the Agreement as described under item 3, the Board of Directors is not aware of any events of material significance for the Company which have occurred since the last balance sheet date.

Annual accounts, annual report and auditor's report for 2021 are available at the Company's website www.nordicnanovector.com and for review at the Company's business office.

The Board of Directors proposes that the General Meeting passes the following resolution:

The Company's share capital is increased pursuant to the Norwegian Public Limited Liability Companies Act section 10-1, on the following terms:

- 1. The Company's share capital shall be increased with NOK 74,407,041.80, through issue of 372,035,209 new shares.*
- 2. The new shares shall each have nominal value of NOK 0.20.*
- 3. The subscription price for the new shares shall be NOK 1.32769 per share. The aggregate subscription amount for the new shares is NOK 493,947,426.64, of which NOK 74,407,041.80 constitutes par value and NOK 419,540,384.84 constitutes share premium.*
- 4. The new shares shall be subscribed by such persons and with such amounts that are set out in Appendix 3 to the minutes. Oversubscription is not permitted.*
- 5. Subscriptions shall be made by the subscribers on a separate subscription form no later than 31 December 2022.*
- 6. Payment for the shares shall be settled by way of set off whereby the investors' claims against the Company pursuant to a loan note issued upon the completion of a transaction agreement of 2 November 2022 are set-off on a NOK-for-NOK basis against the Company's claim for the contribution, cf. section 10-2 (1) of the Norwegian Public Limited Liability Companies Act. The set-off shall be considered settled at the subscription of the shares.*
- 7. The shares give full rights, including rights to dividends, from and including the date of registration of the capital increase in the Register of Business Enterprises.*
- 8. The estimated amount of expenses related to the share capital increase is NOK 500,000. Additional costs have accrued in relation to the strategic process leading up to the agreement to purchase shares in APIM Therapeutics AS.*
- 9. With effect from the registration of the share capital increase with the Norwegian Register of Business Enterprises, section 4 of the articles of association is amended to reflect the share capital and total number of shares after the share capital increase.*
- 10. The resolution is conditional upon the General Meeting passing resolutions in accordance with the resolutions proposed by the Board of Directors under item 3, 5 and 6 on the agenda.*

Item 5 Change of the Company's objective

Reference is made to the statement under item 3. On the basis that the Transaction constitutes an expansion of the Company's business, the Board of Directors proposes that the General Meeting passes a resolution to amend the Articles of Association in order to reflect this change.

The Board of Directors proposes that the General Meeting passes the following resolution:

The Articles of Association section 3 is amended to read as follows:

"The objective of the company is to develop and commercialize innovative drugs targeting oncology indications of high unmet medical need, including any medical products and equipment and to run business related thereto or associated therewith."

The resolution is conditional upon the General Meeting passing resolutions in accordance with the resolutions proposed by the Board of Directors under item 3, 4 and 6 on the agenda. This amendment of the Articles of Association shall take effect upon closing of the Transaction.

Item 6 Election of new Board of Directors

Reference is made to the statement under item 3.

In accordance with the Agreement, a new Board of Directors of the Company shall be elected, consisting of (i) Jan Hendrik Egberts (Chairman), (ii) Malene Brondberg (member), (iii) Erlend Skagseth (member), (iv) Gökhan Batur (member), and (v) an additional board member to be proposed. The Chairman of the Nomination Committee in Nordic Nanovector has been informed of the Agreement and it is expected that the Nomination Committee will assess the composition of the Board of Directors in relation to the next annual general meeting in the Company after the Transaction has been carried out.

The Board of Directors proposes that the General Meeting passes the following resolution:

Joanna Horobin and Karin Meyer resign as board members. Malene Brondberg, Erlend Skagseth, Gökhan Batur and [name] are elected as new board members for a term until the Annual General Meeting in 2023.

The Board of Directors thus consist of:

- *Jan Hendrik Egberts (Chairman)*
- *Malene Brondberg (member)*
- *Erlend Skagseth (member)*
- *Gökhan Batur (member)*
- *[name] (member)*

The resolution is conditional upon the General Meeting passing resolutions in accordance with the resolutions proposed by the Board of Directors under item 3, 4 and 5 on the agenda. The election of a new Board of Directors shall take effect upon closing of the Transaction.

Item 7 Authorisation to the Board of Directors to increase the share capital by up to 20% for specified purposes

Reference is made to the statement under item 3.

On the basis of the share capital increase pursuant to item 4 above, the Board of Directors has proposed that the General Meeting issue an authorisation to the Board of Directors to increase the share capital. The authorisation replaces the authorisation resolved at the Company's Annual General Meeting on 28 April 2022 and will represent 20% of the share capital of the Company after completion of the share capital increase proposed under item 4 on the agenda.

To give the Board of Directors financial flexibility in connection with acquisitions or similar transactions, or to strengthen the Company's equity in general, the Board of Directors proposes that it is given an authorisation to issue shares for these purposes.

It could be in the best interest of the Company and its shareholders that placements of shares are directed at certain named persons and/or enterprises. The Board of Directors requests therefore that the authorisation also encompass the right for the Board of Directors to waive the shareholders' pre-emptive rights.

The Board of Directors proposes that the General Meeting passes the following resolution:

1. *Pursuant to Section 10-14 of the Norwegian Public Limited Companies Act, the Board of Directors is granted an authorisation to increase the Company's share capital, in one or more occurrences, by up to NOK 19,526,478.*
2. *The authorisation may be used to strengthen the Company's equity, for general corporate purposes, including but not limited to financing of acquisitions of other companies, businesses or assets, including issuance of consideration shares in connection with the above mentioned transactions.*
3. *The authorisation is valid until the Company's Annual General Meeting in 2023, but no longer than 30 June 2023.*
4. *The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.*
5. *The authorisation comprises share capital increases against contribution in cash and in kind and the right to impose special obligations on the Company etc, cf. Section 10-2 of the Norwegian Public Limited Companies Act. The authorisation covers resolutions on mergers as provided in section 13-5 of the Norwegian Public Limited Companies Act.*

The resolution is conditional upon the General Meeting passing resolutions in accordance with the resolutions proposed by the Board of Directors under item 3, 4, 5 and 6 on the agenda.
